Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4196)
All Articles published online
|
Aug 14, 2015 (publication date) through Nov 27, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Salmerón J, Vinaixa C, Berenguer R, Pascasio JM, Sánchez Ruano JJ, Serra M&, Gila A, Diago M, Romero-Gómez M, Navarro JM, Testillano M, Fernández C, Espinosa D, Carmona I, Pons JA, Jorquera F, Rodriguez FJ, Pérez R, Montero JL, Granados R, Fernández M, Martín AB, Muñoz de Rueda P, Quiles R, Alhambra Spanish Study Group. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis. World J Gastroenterol 2015; 21(30): 9163-9174 [PMID: 26290644 DOI: 10.3748/wjg.v21.i30.9163] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v21/i30/9163.htm |
| Number | Citing Articles |
| 1 |
Timothy A. Bach, Kathy Zaiken. Outcomes of treatment with direct-acting antivirals for infection with hepatitis C virus genotypes 1–4 in an ambulatory care setting. American Journal of Health-System Pharmacy 2017; 74(5_Supplement_1): S1 doi: 10.2146/ajhp160567
|
| 2 |
Cristina Scavone, Liberata Sportiello, Concetta Rafaniello, Annamaria Mascolo, Maurizio Sessa, Francesco Rossi, Annalisa Capuano. New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs). Expert Opinion on Drug Safety 2016; 15(sup2): 85 doi: 10.1080/14740338.2016.1221396
|
| 3 |
Isabel Conde, Carmen Vinaixa, Marina Berenguer. Hepatitis C-related cirrhosis. Current status. Medicina Clínica (English Edition) 2017; 148(2): 78 doi: 10.1016/j.medcle.2016.09.035
|
| 4 |
Emma Gray, Suzanne Norris, Susanne Schmitz, Aisling O'Leary. Do disparities between populations in randomized controlled trials and the real world lead to differences in outcomes?. Journal of Comparative Effectiveness Research 2017; 6(1): 65 doi: 10.2217/cer-2016-0042
|
| 5 |
Javier Ampuero, Manuel Romero-Gómez. Pharmacogenetics of Ribavirin-Induced Anemia in Hepatitis C. Pharmacogenomics 2016; 17(14): 1587 doi: 10.2217/pgs.16.28
|
| 6 |
João Paulo Vilela Rodrigues, Maurílio de Souza Cazarim, Silvana Gama Florencio Chachá, Ana de Lourdes Candolo Martinelli, Leonardo Régis Leira Pereira. Cost-effectiveness analysis is a mandatory strategy for health systems: evidence from a study involving therapies for hepatitis C. Cadernos de Saúde Pública 2020; 36(2) doi: 10.1590/0102-311x00036619
|
| 7 |
Silvana Gama Florencio Chachá, João Paulo Vilela Rodrigues, Roberta Chaves Araújo, Leonardo Régis Leira Pereira, Márcia Guimarães Villanova, Fernanda Fernandes Souza, Rodrigo de Carvalho Santana, Ana de Lourdes Candolo Martinelli. First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients. Revista da Sociedade Brasileira de Medicina Tropical 2018; 51(2): 146 doi: 10.1590/0037-8682-0153-2017
|
| 8 |
Mònica Pons, Begoña Santos, Macarena Simón-Talero, Meritxell Ventura-Cots, Mar Riveiro-Barciela, Rafael Esteban, Salvador Augustin, Joan Genescà. Rapid liver and spleen stiffness improvement in compensated advanced chronic liver disease patients treated with oral antivirals. Therapeutic Advances in Gastroenterology 2017; 10(8): 619 doi: 10.1177/1756283X17715198
|
| 9 |
Isabel Conde, Carmen Vinaixa, Marina Berenguer. Cirrosis por hepatitis C. Estado actual. Medicina Clínica 2017; 148(2): 78 doi: 10.1016/j.medcli.2016.09.019
|